Rasagiline: The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer’s Disease, ALS and Aging

mdpi.com/2073-4409/12/5/763...

However, accumulating evidence has shown that iron-dependent oxidative stress (OS), increased iron levels, and monoamine oxidase (MAO)-B activity, as well as reduced antioxidant levels and activities in the brain, maybe major pathogenic factors in neurodegenerative diseases.

...and chemically attached to the propargyl moiety of the anti-Parkinsonian MAO-B inhibitor, rasagiline (Azilect®) [125] (Figure 2) thus inheriting some of their neuroprotective/neurorestorative properties

and have additional neurorestorative activity associated with the introduction of a propargylamine monoamine oxidase (MAO) inhibitor moiety of anti-Parkinson drug rasagiline (Azilect®). M30 is also a potent, brain-selective MAO inhibitor that inhibits both MAO-A and MAO-B in the brain while only inhibiting gastrointestinal MAOs marginally in vivo.

[4000Nights]

Can someone explain this in layman's terms.

[kaypeeoh in reply to 4000Nights]

Just a guess based on my reading the article. MAO breaks down protein chemicals like dopamine. When inhibited the dopamine stays longer in the brain. What's new is that at the same time Rasag crosses the BBB and chelates iron so that iron doesn't accumulate in the substantia nigra.

[Hidden in reply to kaypeeoh]

Thanks for simplifying.